Compare VSTS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | COLL |
|---|---|---|
| Founded | 1936 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2023 | 2015 |
| Metric | VSTS | COLL |
|---|---|---|
| Price | $9.90 | $34.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.88 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 967.9K | 570.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | ★ $2,734,839,000.00 | $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | ★ N/A | $19.10 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $3.98 | $25.87 |
| 52 Week High | $9.80 | $50.79 |
| Indicator | VSTS | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 80.59 | 44.86 |
| Support Level | $7.24 | $31.18 |
| Resistance Level | N/A | $36.20 |
| Average True Range (ATR) | 0.34 | 1.30 |
| MACD | 0.18 | 0.44 |
| Stochastic Oscillator | 95.15 | 57.72 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.